背景:利拉鲁肽治疗2型糖尿病肾病(T2DN)的疗效仍存在争议。因此,我们进行了这项荟萃分析,以系统评价利拉鲁肽对T2DN患者的临床疗效.
方法:八个数据库(PubMed,WebofScience,Cochrane图书馆,EMBASE,中国国家知识基础设施(CNKI),万方数据库,中国科技期刊数据库,和中国生物学医学数据库(CBM))搜索已发表的文章,以评估利拉鲁肽在T2DN受试者中的临床疗效。Revman5.3和Stata13软件用于分析和绘图。
结果:共筛选了18项纳入1580例糖尿病肾病患者的随机对照试验。我们发现UACR的水平,Scr,用利拉鲁肽治疗的T2DN患者实验组的Cysc低于未用利拉鲁肽干预的对照组。利拉鲁肽还降低了血糖水平(包括FBG,PBG,和HbA1c),体重指数(BMI),和抗炎指标(TNF-α,IL-6).然而,实验组与对照组的BUN和eGFR差异无统计学意义。
结论:利拉鲁肽降低血糖水平,BMI,肾脏结局指标,T2DN患者血清炎症因子水平,提示利拉鲁肽对肾功能的有益作用。
BACKGROUND: The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients.
METHODS: Eight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database, and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 software were used for analyses and plotting.
RESULTS: A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in the experimental group of T2DN patients treated with liraglutide than in the control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG, and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF-α, IL-6). However, there was no significant difference in BUN and eGFR between the experimental group and the control group.
CONCLUSIONS: Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.